Results 21 to 30 of about 2,223,665 (257)

Intracellular magnetic hyperthermia reverses sorafenib resistance in hepatocellular carcinoma through its action on signaling pathways

iScience
Summary: Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), unfortunately encounters resistance in most patients, leading to disease progression.
Hugang Li, Zirui Ye, Xun Wang, Jianlan Yuan, Jingyi Guo, Chen Liu, Bin Yan, Haiming Fan, Yi Lyu, Xiaoli Liu   +9 more
doaj   +2 more sources

Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma [PDF]

Cellular Physiology and Biochemistry, 2017
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and prognosis remains unsatisfactory since the disease is often diagnosed at the advanced stages.
Ting Sun, Hongchun Liu, Liang Ming
doaj   +3 more sources

Mechanisms of Sorafenib Resistance in HCC Culture Relate to the Impaired Membrane Expression of Organic Cation Transporter 1 (OCT1) [PDF]

Journal of Hepatocellular Carcinoma
Srinivas Chava,1 Nergiz Ekmen,2 Pauline Ferraris,1 Yucel Aydin,2 Krzysztof Moroz,1 Tong Wu,1 Swan N Thung,3 Srikanta Dash1,2,4 1Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA; 2Department ...
Chava S, Ekmen N, Ferraris P, Aydin Y, Moroz K, Wu T, Thung SN, Dash S   +7 more
doaj   +1 more source

IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis [PDF]

Frontiers in Immunology
IntroductionSorafenib is currently the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Nevertheless, sorafenib resistance remains a huge challenge in the clinic.
Junzhang Chen, Shiran Sun, Hui Li, Xiong Cai, Chidan Wan   +4 more
doaj   +2 more sources

Nanocomposites to Overcoming Sorafenib Resistance in Hepatocellular Carcinoma Therapy. [PDF]

Int J Nanomedicine
The emergence of drug resistance is the major obstacle to the clinical application of sorafenib (SOR), which often leads to disease progression, recurrence, and even death in hepatocellular carcinoma (HCC) patients. Nanocomposite-mediated drug delivery enhances targeting precision and therapeutic utilization efficiency.
Liu J, Zhou S, Wei Y, Du J, Jia F, Dong W, Cao Y, Shi Z, Mu H, Chen L, Yu S.   +10 more
europepmc   +5 more sources

The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma

Frontiers in Oncology, 2021
BackgroundSorafenib is the first molecular-targeted drug for the treatment of advanced hepatocellular carcinoma (HCC). However, its treatment efficiency decreases after a short period of time because of the development of drug resistance.
Yi Shi, Yi Shi, Xiaojiang Wang, Xiaojiang Wang, Qiong Zhu, Gang Chen, Gang Chen   +6 more
doaj   +1 more source

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis

Journal of Experimental & Clinical Cancer Research, 2023
Background Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore
Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng, Chuanyong Guo   +13 more
doaj   +1 more source

Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells

Frontiers in Pharmacology, 2021
The multireceptor tyrosine kinase inhibitor sorafenib is a Food and Drug Administration-approved first-line drug for the treatment of advanced liver cancer that can reportedly extend overall survival in patients with advanced hepatocellular carcinoma ...
Wubin He, Xiaoxu Huang, Bradford K. Berges, Yue Wang, Ni An, Rongjian Su, Yanyan Lu   +6 more
doaj   +1 more source

Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma

Biomedicine & Pharmacotherapy, 2022
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Although sorafenib is a standard first-line molecule-targeted drug against advanced HCC, the drug resistance development and adverse side effects usually limit its efficacy.
Jialiang, Luo, Lei, Li, Zhengyumeng, Zhu, Bo, Chang, Fan, Deng, Di, Wang, Xiao, Lu, Daming, Zuo, Qingyun, Chen, Jia, Zhou   +9 more
openaire   +2 more sources

Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression

Infectious Agents and Cancer, 2021
Background HBV promotes cell survival by upregulating the expression of the cellular inhibitor of apoptosis protein 2 (cIAP2), however whether it is involved in HBV-induced sorafenib resistance in liver cancer remains unclear.
Shouhua Zhang, Nuoya Li, Yanling Sheng, Wen Chen, Qiangliang Ma, Xin Yu, Jianping Lian, Junquan Zeng, Yipeng Yang, Jinlong Yan   +9 more
doaj   +1 more source